LETTER TO EDITOR

Serum bile acids in liver cirrhosis promote neutrophil dysfunction

Dear Editor,

Neutrophil dysfunction is common in cirrhotic patients and is associated with mortality. Given the highly increased bile acid (BA) levels in liver cirrhosis and their previously shown anti-inflammatory effects, we studied if BAs contribute to the development of cirrhosis-associated neutrophil dysfunction.

We analysed phagocytosis and reactive oxygen species (ROS) production of neutrophils and serum BAs in cirrhotic patients (n = 109) and healthy controls (n = 21) (Table 1, Tables S3–S4, Supplementary Material and Methods). The cirrhotic cohort had a larger proportion of non-phagocytosing neutrophils in whole blood (Figure S1A,B) and dysregulated ROS production with more neutrophils from cirrhotics producing ROS without a stimulus or in response to N-formyl-met-leu-phe (fMLF), and less neutrophils from cirrhotics producing ROS in response to E. coli compared to healthy controls (Figure S1C–E). The level of intracellular ROS produced by these neutrophils was not significantly different between the groups (Figure S2A–C).

Serum BA composition was also different in cirrhotic patients compared to healthy controls (Figures S3A,B and S4A,B). The relative abundance of total deoxycholic acid (DCA) in cirrhotic patients was lower than in healthy controls (Figure S3C, Table S5). Secondary, unconjugated and glycine-conjugated BAs were significantly less abundant in cirrhotic patients’ sera compared to healthy sera. Taurine-conjugated BAs were significantly more abundant in cirrhotic sera compared to healthy sera (Figure S3D–G, Table S5).

Neutrophil function and BA composition were significantly different between the groups according to liver cirrhosis severity and aetiology as shown by univariate (Figures S5A–E and S6A–E, Tables S6 and S7) and multivariate analyses (Figures S7A–D, S8A–F and S9A–F). The phagocytic capacity of neutrophils was lowest in hepatitis C patients (Figure S6B), who had the highest relative abundance of total chenodeoxycholic acid (CDCA) in serum (Table S7).

Further analysis showed that higher total CDCA relative abundance and lower ursodeoxycholic acid (UDCA) relative abundance could significantly predict the decreased neutrophil phagocytosis in cirrhotic patients. Lower UDCA relative abundance could also predict the dysfunctional ROS production in response to E. coli (Figure S10A–C, Table S8).

In order to validate the findings observed with clinical samples in vitro, we treated neutrophils from healthy donors with an artificial ‘BA mix’ that mimicked the BA composition in cirrhotic cohort, as well as with individual or total (sum of unconjugated, taurine and glycine conjugated forms) BAs in pathophysiologically relevant concentrations (Figures 1A, 2A and 3A, Tables S1 and S2, Supplementary Material and Methods). Cytotoxicity of BAs was ruled out (Figure S11).

In our experiments ‘BA mix’ significantly induced ROS production by unstimulated neutrophils (Figure 1B,C). ROS production in response to fMLF or E. coli, however, was not changed after treatment with ‘BA mix’ (Figure S14A,B). Further experiments with individual BAs revealed that total LCA, but not other BAs, caused increased ROS production (Figure 1D,E, Figure S12A), with glycolithocholic acid having the most pronounced effect (Figure S13A). LCA has been shown to bind Takeda G protein-coupled Receptor 5, whose activation can trigger ROS production, which may explain the effects of LCA and its conjugates.

Total CDCA and total LCA reduced ROS production in response to fMLF (Figure 2B,D,F), but not their unconjugated and conjugated forms individually (Figure S13B,C). CDCA has been previously described to inhibit neutrophil chemotaxis and calcium flux, via competing with fMLF for binding to the Formyl Peptide Receptor 1 (FPR1). The decreased ROS production caused by pre-incubation with total LCA might be a consequence of cell exhaustion following the LCA-mediated ROS release.

Total CDCA, its unconjugated and conjugated forms individually, as well as total DCA caused a decrease in ROS...
TABLE 1 Demographic characteristics and liver function parameters of cirrhotic patients depending on liver cirrhosis aetiology (median ± interquartile range)

| Characteristic     | Alcoholic (n = 54) | HCV (n = 32) | Other (n = 23) | p-value |
|--------------------|--------------------|--------------|---------------|---------|
| Age (years)        | 56 ± 12            | 60 ± 9       | 55 ± 14       | n.s.    |
| Sex (Male/Female)  | 42/12              | 22/10        | 13/10         | n.s.    |
| Child-Pugh group (A/B+C, n) | 37/17              | 25/7         | 17/6          | n.s.    |
| Child-Pugh score   | 6 ± 2              | 5 ± 1        | 5 ± 2         | n.s.    |
| MELD score         | 12 ± 6             | 8 ± 4        | 10 ± 7        | p = .014<sup>a</sup> |
| AST (U/l)          | 44 ± 26            | 91 ± 72      | 40 ± 38       | p < .001<sup>b</sup> |
| ALT (U/l)          | 32.5 ± 19          | 70 ± 80      | 34 ± 38       | p < .001<sup>c</sup> |

| Characteristic     |                |              |               |         |
|--------------------|----------------|--------------|---------------|---------|
| GGT (U/l)          | 105.5 ± 176    | 114.5 ± 135  | 120.5 ± 285   | n.s.    |
| AP (U/l)           | 109 ± 74       | 94 ± 45      | 105 ± 100     | n.s.    |
| Bilirubin (mg/dl)  | 1.5 ± 1.6      | .9 ± .9      | 1.1 ± 3.5     | p = .030<sup>d</sup> |
| INR (ratio)        | 1.3 ± .3       | 1.1 ± .3     | 1.2 ± .3      | p = .030<sup>e</sup> |
| Creatinine (mg/dl) | .8 ± .3        | .8 ± .2      | .8 ± .3       | n.s.    |
| Albumin (g/dl)     | 4.0 ± 1.1      | 4.0 ± .8     | 4.5 ± 1.0     | n.s.    |
| Neutrophils (x10<sup>9</sup>/l) | 2.9 ± 1.4 | 2.6 ± 1.0 | 3.1 ± 2.8 | n.s. |

Note: Median ± interquartile range. Group ‘Other’ included patients with alpha-1 antitrypsin deficiency (n = 1), secondary sclerosing cholangitis in critically ill patients (n = 2), hepatitis B (n = 4), haemochromatosis (n = 2), non-alcoholic fatty liver disease (n = 5), medication associated (n = 2), Wilson disease (n = 3) and cryptogenic cirrhosis (n = 4). ALT, alanine transaminase; AP, alkaline phosphatase; AST, aspartate transaminase; GGT, gamma-glutamyl transferase; HCV, hepatitis C virus; INR, international normalized ratio; MELD, model for end-stage liver disease; n.s., not significant.

<sup>a</sup>Between HCV and alcoholic.
<sup>b</sup>Between HCV and other.
<sup>c</sup>Between other and alcoholic groups.

FIGURE 1 Total LCA induce ROS production by unstimulated neutrophils. (A) Experimental setup. (B–E) ROS production of isolated healthy donor neutrophils after treatment with bile acid (BA)/vehicle. (C and E) Representative examples and (B and D) total ROS production over time. ROS data were normalised and compared to vehicle-treated control (PBS) and represent a minimum of four separate experiments. Data are presented for bile acids, which significantly influenced ROS production; error bars, SEM; *p < .05, **p < .01, ***p < .001 (unpaired t-test). BAs, bile acids; LCA, lithocholic acid; PBS, phosphate-buffered saline; RLUs, relative light units; ROS, reactive oxygen species; SEM, standard error of the mean.
Bile acids inhibit neutrophil ROS production in response to fMLF and *E. coli*. (A) Experimental setup. (B–G) ROS production of isolated healthy donor neutrophils after treatment with bile acid/vehicle and stimulation with (B, D, and F) fMLF (1.45 μM) or (C, E, and G) *E. coli* (40 bacteria/cell). (D–G) Representative examples and (B and C) total ROS production over time. Total ROS data were normalised and compared to vehicle-treated (PBS or different concentrations of DMSO) stimulated control and represent a minimum of four separate experiments. Data are presented for bile acids, which significantly influenced ROS production; error bars, SEM; *p < .05, **p < .01, ***p < .001 (unpaired t-test). CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; DMSO, dimethyl sulfoxide; fMLF, N-formyl-met-leu-phe; LCA, lithocholic acid; PBS, phosphate-buffered saline; RLUs, relative light units; ROS, reactive oxygen species; SEM, standard error of the mean.

production in response to *E. coli* (Figure 2C,E,G, Figure S13D,E). DCA has previously been described to inhibit neutrophil chemotaxis and calcium mobilisation and is also thought to be able to inhibit FPR1 signalling.9 There were no significant changes in ROS production after the treatment with total cholic acid (CA) and total UDCA (Figure S12A–C). Reduction in ROS production in response to fMLF and *E. coli* caused by BAs may contribute to an explanation for the reduced ROS production, which has been shown previously in neutrophils from cirrhotic patients.10

We also tested if treatment with BAs influence phagocytosis in vitro (Figure 3A). ‘BA mix’ did not significantly affect neutrophil phagocytosis (Figure 3B); however, total CDCA and total DCA (but neither their unconjugated and conjugated forms individually, nor total CA, total UDCA and total LCA) significantly reduced phagocytosis of *E. coli* (Figure 3C,D; Figures S15A,B and S16A–C). The inhibitory effects of total CDCA and total DCA were reversible – neutrophil phagocytosis was not inhibited anymore after the BAs were washed out from the assay medium (Figure 3E–G).

In conclusion, we performed an extensive analysis of neutrophil function and serum BA composition in a large cohort of cirrhotic patients. We show that BAs are associated with neutrophil dysfunction in the clinical data from cirrhotic patients, as well as in the experiments where
we directly treated neutrophils with BAs. These findings should be validated in patients with more severe stages of cirrhosis, and the molecular mechanisms of the observed BA effects on neutrophil function need to be explored in further studies. The reversibility of neutrophil dysfunction caused by BAs, which we observed, suggests that therapeutic modulation of serum BA profile toward a ‘healthy’ composition could potentially not only prevent neutrophil dysfunction but also restore already impaired neutrophil function in cirrhotic patients. This in turn will allow reducing bacterial infections and associated morbidity and mortality in liver cirrhosis. BA profile modulation may be achieved by oral intake of BAs or modified BAs and by targeting the gut microbiome involved in BA metabolism.

**ACKNOWLEDGEMENTS**

The authors thank Bianca Schmerboeck for the technical assistance, and Utsa Karmakar and Julia Chu (CIR, University of Edinburgh) for helpful discussions. They thank Kellie McDonald for English language proofreading of the manuscript and the Computational Bioanalytics core facility (ZMF, Medical University Graz) for help with statistics as well as the Austrian Science Fund (FWF), the Medical University Graz and the Doctoral College ‘Molecular fundamentals of inflammation’ (W1241) for the provision of funding and facilities.

**CONFLICT OF INTEREST**

All authors have nothing to disclose.
**FUNDING INFORMATION**
Austrian Science Fund FWF (W1241) and the Medical University Graz through the PhD Program Molecular Fundamentals of Inflammation (DK-MOLIN); Medical Research Council (MRC) MR/S008020/1.

Irina Balazs¹,² 🌐
Angela Horvath¹,² 🌐
Bettina Leber³ 🌐
Nicole Feldbacher¹,² 🌐
Wolfgang Sattler⁴,⁵ 🌐
Florian Rainer¹ 🌐
Günter Fauler⁶ 🌐
Sonja Vermeren⁷ 🌐
Vanessa Stadlbauer¹,² 🌐

¹ Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria
² Center for Biomarker Research in Medicine (CBmed), Graz, Austria
³ Department of Surgery, Division of Transplantation Surgery, Medical University of Graz, Graz, Austria
⁴ Gottfried Schatz Research Center (for Cell Signaling, Metabolism and Aging), Division of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria
⁵ Center for Explorative Lipidomics, BioTechMed Graz, Graz, Austria
⁶ Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
⁷ Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK

**Correspondence**
Vanessa Stadlbauer, Department of Internal Medicine, Division of Gastroenterology und Hepatology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
Email: vanessa.stadlbauer@medunigraz.at

**ORCID**
Irina Balazs 🌐 https://orcid.org/0000-0003-2026-3521
Angela Horvath 🌐 https://orcid.org/0000-0001-7279-0628

**REFERENCES**
1. Bernsmeier C, van der Merwe S, Perianin A. Innate immune cells in cirrhosis. J Hepatol. 2020;73(1):186-201.
2. Taylor NJ, Vijay GKM, Abeles RD, et al. The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality. Aliment Pharmacol Ther. 2014;40(6):705-715.
3. Liu N, Feng J, Lv Y, et al. Role of bile acids in the diagnosis and progression of liver cirrhosis: a prospective observational study. Exp Ther Med. 2019;18(5):4058-4066.
4. Haselow K, Bode JG, Wammers M, et al. Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages. J Leukoc Biol. 2013;94(4):1253-1264.
5. Pols TWH, Puchner T, Korkmaz HI, Vos M, Soeters MR, de Vries CJM. Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the vitamin D receptor. PLoS One. 2017;12(5):e0176715.
6. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278(11):9435-9440.
7. Reich M, Deutschmann K, Sommerfeld A, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut. 2016;65(3):487-501.
8. Chen X, Yang D, Shen W, et al. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm Res. 2000;49(12):744-755.
9. Chen X, Mellon RD, Yang L, Dong H, Oppenheim JJ, Howard OM. Regulatory effects of deoxycholic acid, a component of the anti-inflammatory traditional Chinese medicine Niuhuang, on human leukocyte response to chemoattractants. Biochem Pharmacol. 2002;63(3):533-541.
10. Rolas L, Makhezer N, Hadjoudj S, et al. Inhibition of mammalian target of rapamycin aggravates the respiratory burst defect of neutrophils from decompensated patients with cirrhosis. Hepatology. 2013;57(3):1163-1171.

**SUPPORTING INFORMATION**
Additional supporting information may be found in the online version of the article at the publisher’s website.